Companies Jan 26, 2023 Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer Jan 25, 2023 Labcorp, VieCure Collaborate on NGS, Software for Cancer Diagnosis Jan 24, 2023 New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions Premium Jan 24, 2023 Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test Jan 23, 2023 Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment Jan 20, 2023 Astellas' Zolbetuximab Plus Chemo Benefits CLDN18.2-Positive, HER2-Negative Gastric Cancer Patients Premium Jan 20, 2023 FDA Approves Seagen's Tukysa, Genentech's Herceptin for HER2-Positive Colorectal Cancer Patients Jan 19, 2023 In Brief This Week: Strata Oncology, Orphagen Pharmaceuticals, Hutchmed, MD Anderson Cancer Center Jan 19, 2023 Colorectal Cancer Detection Data from CellMax Life Bodes Well for Planned FDA Bid Premium Jan 19, 2023 Invitae Bets on Oncology Portfolio to Drive Growth as it Streamlines, Integrates Test Services Premium Jan 19, 2023 Liquid Biopsy Biomarker Score Predicts Relapse in Lymphoma Patients After CAR T-Cell Treatment Premium Jan 19, 2023 Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer Jan 19, 2023 Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug Jan 19, 2023 Caris Life Sciences Raises $400M in Senior Secured Debt Financing Jan 18, 2023 Penn Scientists Testing Out CAR T-Cell Therapy Gel to Prevent Breast Cancer Recurrence Post-Surgery Premium Jan 18, 2023 Freenome Partners With Geisinger to Recruit Patients for Multi-Cancer Screening Study Jan 17, 2023 PamGene, Alithea Genomics, Lausanne University get €1M for Pan-Cancer Blood Test Jan 13, 2023 In Brief This Week: Legend Biotech, Point Biopharma, AstraZeneca, Daiichi Sankyo, Takeda, Micronoma Jan 12, 2023 JP Morgan Healthcare Conference, Day 3: Iovance Biotherapeutics, Biomea Fusion, ADC Therapeutics Jan 11, 2023 JP Morgan Healthcare Conference, Day 2: Roche, Zai Lab, Revolution Medicines, Ideaya Biosciences Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
